Clinical trial NCT04881851 - References

Polycystic Ovary Syndrome — Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment

Citation(s)

•   Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN; PCOS/Troglitazone Study Group
  Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001 Apr;86(4):1626-32.
•   Bae SM, Bae MN, Kim EY, Kim IK, Seo MW, Shin JK, Cho SR, Jeong GH
  Recurrent Insulin Autoimmune Syndrome Caused by a-Lipoic Acid in Type 2 Diabetes. Endocrinol Metab (Seoul). 2013 Dec;28(4):326-30. doi: 10.3803/EnM.2013.28.4.326. Epub 2013 Dec 12.
•   Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE
  Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006 Feb;29(2):300-5.
•   Baptiste CG, Battista MC, Trottier A, Baillargeon JP
  Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010 Oct;122(1-3):42-52. doi: 10.1016/j.jsbmb.2009.12.010. Epub 2009 Dec 28. Review.
•   Barua S, Kuizon S, Junaid MA
  Folic acid supplementation in pregnancy and implications in health and disease. J Biomed Sci. 2014 Aug 19;21:77. doi: 10.1186/s12929-014-0077-z. Review.
•   Capasso I, Esposito E, Maurea N, Montella M, Crispo A, De Laurentiis M, D'Aiuto M, Frasci G, Botti G, Grimaldi M, Cavalcanti E, Esposito G, Fucito A, Brillante G, D'Aiuto G, Ciliberto G
  Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials. 2013 Aug 28;14:273. doi: 10.1186/1745-6215-14-273.
•   Carlomagno G, Unfer V
  Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):931-6. Review.
•   Cheang KI, Baillargeon JP, Essah PA, Ostlund RE Jr, Apridonize T, Islam L, Nestler JE
  Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism. 2008 Oct;57(10):1390-7. doi: 10.1016/j.metabol.2008.05.008.
•   De Leo V, la Marca A, Petraglia F
  Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev. 2003 Oct;24(5):633-67. Review.
•   DeFronzo RA, Tobin JD, Andres R
  Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-23.
•   Dunaif A
  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774-800. Review.
•   Elnashar A, Abdelmageed E, Fayed M, Sharaf M
  Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod. 2006 Jul;21(7):1805-8. Epub 2006 Mar 16.
•   Fenkci V, Fenkci S, Yilmazer M, Serteser M
  Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003 Jul;80(1):123-7.
•   Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N
  Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab. 2002 Feb;87(2):569-74.
•   Franks S
  Polycystic ovary syndrome. N Engl J Med. 1995 Sep 28;333(13):853-61. Review. Erratum in: N Engl J Med 1995 Nov 23;333(21):1435.
•   Gerli S, Mignosa M, Di Renzo GC
  Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003 Nov-Dec;7(6):151-9.
•   Giordano D, Corrado F, Santamaria A, Quattrone S, Pintaudi B, Di Benedetto A, D'Anna R
  Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause. 2011 Jan;18(1):102-4. doi: 10.1097/gme.0b013e3181e8e1b1.
•   Gray DS, Bray GA, Gemayel N, Kaplan K
  Effect of obesity on bioelectrical impedance. Am J Clin Nutr. 1989 Aug;50(2):255-60.
•   Hatch R, Rosenfield RL, Kim MH, Tredway D
  Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981 Aug 1;140(7):815-30.
•   Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE
  Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002 Nov-Dec;8(6):417-23.
•   Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K
  Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med. 1999 Aug;27(3-4):309-14.
•   Kozakowski J, Zgliczynski W
  Body composition, glucose metabolism markers and serum androgens - association in women with polycystic ovary syndrome. Endokrynol Pol. 2013;64(2):94-100.
•   Masharani U, Gjerde C, Evans JL, Youngren JF, Goldfine ID
  Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2010 Mar 1;4(2):359-64.
•   Matsuda M, DeFronzo RA
  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep;22(9):1462-70.
•   Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M
  Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000 Jan;85(1):139-46.
•   Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M
  The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab. 1996 Mar;81(3):952-60.
•   Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R
  Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998 Jun 25;338(26):1876-80.
•   Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G
  Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20.
•   Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group
  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. Review.
•   Saltiel AR
  Second messengers of insulin action. Diabetes Care. 1990 Mar;13(3):244-56. Review.
•   Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM
  Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009 Oct;1790(10):1149-60. doi: 10.1016/j.bbagen.2009.07.026. Epub 2009 Aug 4. Review.
•   Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH
  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012 May 16;(5):CD003053. doi: 10.1002/14651858.CD003053.pub5. Review. Update in: Cochrane Database Syst Rev. 2017 Nov 29;11:CD003053.
•   Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
  Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008 Mar;23(3):462-77. doi: 10.1093/humrep/dem426. Erratum in: Hum Reprod. 2008 Jun;23(6):1474.

Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment

Details for clinical trial NCT04881851